The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Investigating JAK2V617F as a therapeutic target in MPNs
Ross Levine, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses his work investigating JAK2V617F as a therapeutic target in myeloproliferative neoplasms (MPNs). Through the development of an endogenously expressed JAK2V617F dual-recombinase knock-in/knock-out model, Dr Levine and his team were able to demonstrate that JAK2V617F deletion eradicates disease-sustaining MPN stem cells and reverses manifestations of the disease. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Dr Levine is on the supervisory board of Qiagen and is a scientific advisor to Loxo (until 2019), Imago, C4 Therapeutics, Mana, Auron, Ajax, Kurome, Mission Bio, Scorpion, and Isoplexis, which each include an equity interest. He receives research support from and consulted for Celgene and Roche, he has received research support from Constellation, Roche, and Prelude Therapeutics, and he has consulted for Bridge Therapeutics, BMS, Lilly, Incyte, Novartis and Janssen. He has received honoraria from Astra Zeneca, Constellation, Lilly and Amgen for invited lectures and from Gilead for grant reviews.
